2025 Acute Coronary Syndrome Guideline: Missing the Boat on CYP2C19 Genotyping
Journal of the American Heart Association · 2026
DOI: 10.1161/jaha.125.047768 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of the American Heart Association, 2026. Verfasst von Larisa H Cavallari und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacotherapy and Translational Research and Center for Pharmacogenomics and Precision, Medicine College of Pharmacy University of Fl…. Hauptthemen laut MEDLINE: Cytochrome P-450 CYP2C19, Acute Coronary Syndrome, Practice Guidelines as Topic, Platelet Aggregation Inhibitors. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
The 2025 American College of Cardiology/American Heart Association/American College of Emergency Physicians/National Association of Emergency Medical Services Physicians/Society for Cardiovascular Angiography & Interventions acute coronary syndrome guideline focuses on strategies to reduce bleeding risk with antiplatelet therapy yet lacks any recommendation related to CYP2C19 genotyping. The impact of CYP2C19 loss‐of‐function alleles on the effectiveness of clopidogrel is well documented, and although prasugrel and ticagrelor more effectively reduce the risk for atherothrombotic events compared with clopidogrel in patients with a CYP2C19 loss‐of‐function allele, clopidogrel reduces bleeding risk without an increase in atherothrombotic events compared with prasugrel or ticagrelor in those without a loss‐of‐function allele. Accordingly, an American Heart Association Scientific Statement supports CYP2C19 genetic testing before oral P2Y 12 inhibitors are prescribed. This commentary summarizes the evidence in support of CYP2C19 ‐guided P2Y 12 inhibitor selection in the context of other 2025 acute coronary syndrome guideline recommendations and urges future guidelines to incorporate recommendations for CYP2C19 genotyping, especially for those at high bleeding risk.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacotherapy and Translational Research and Center for Pharmacogenomics and Precision, Medicine College of Pharmacy University of Florida Gainesville FL USA.
- Division of Pharmacotherapy and Experimental Therapeutics, Eshelman School of Pharmacy University of North Carolina at Chapel Hill Chapel Hill NC USA.
- Division of Cardiology and McAllister Heart Institute, School of Medicine University of North Carolina at Chapel Hill Chapel Hill NC USA.
- University of Maryland School of Medicine Department of Medicine and Program for Personalized and Genomic Medicine Baltimore MD USA.
- Department of Clinical Pharmacy University of Michigan College of Pharmacy Ann Arbor MI USA.
- Center for Individualized and Genomic Medicine Research (CIGMA) Henry Ford Health System Detroit MI USA.
ORCID-Profile: Larisa H Cavallari, Craig R Lee, Amber L Beitelshees, Jasmine A Luzum, George A Stouffer, Jurriën M Ten Berg, Wout W A van den Broek, Naveen L Pereira, Dirk Sibbing, Dominick J Angiolillo
Zitieren
APA
Cavallari, L. H., Lee, C. R., Beitelshees, A. L., Luzum, J. A., Stouffer, G. A., Ten Berg, J. M., van den Broek, W. W. A., Pereira, N. L., Sibbing, D., & Angiolillo, D. J. (2026). 2025 Acute Coronary Syndrome Guideline: Missing the Boat on CYP2C19 Genotyping. Journal of the American Heart Association. https://doi.org/10.1161/jaha.125.047768
Vancouver
Cavallari LH, Lee CR, Beitelshees AL, Luzum JA, Stouffer GA, Ten Berg JM, et al. 2025 Acute Coronary Syndrome Guideline: Missing the Boat on CYP2C19 Genotyping. Journal of the American Heart Association. 2026. doi:10.1161/jaha.125.047768
BibTeX
@article{Cavallari2026,
author = {Cavallari, Larisa H and Lee, Craig R and Beitelshees, Amber L and Luzum, Jasmine A and Stouffer, George A and Ten Berg, Jurriën M and van den Broek, Wout W A and Pereira, Naveen L and Sibbing, Dirk and Angiolillo, Dominick J},
title = {2025 Acute Coronary Syndrome Guideline: Missing the Boat on CYP2C19 Genotyping},
journal = {Journal of the American Heart Association},
year = {2026},
doi = {10.1161/jaha.125.047768}
}
EUVIMED